Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Abramson Cancer Center at Penn Medicine
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06613841CT.gov Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| AXUMIN (this asset) | Abramson Cancer Center at Penn Medicine | Early P1 | C · 39 |
| Tvi-Brain-1 | TVAX Biomedical | P2/3 | B |
| Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide | Oblato, Inc. | P2 | B |
| Belinostat | Emory University | P2 | CCC |
| Ruxolitinib | Baptist Health South Florida | P2 | CCC |
| Avelumab | Clinique Neuro-Outaouais | P2 | CCC |
| Pembrolizumab | University Hospital, Geneva | P1/2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Zhongnan Hospital | P1/2 | CC |
| ima950 | University Hospital, Geneva | P1/2 | CC |
+14 more in the Brain Glioblastoma cohort
Other indications for AXUMIN
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P3 | BB · 66 |
| Ovarian Carcinoma | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. AXUMIN in Brain Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axumin-brain-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →